TG Therapeutics
TGTX
235 hedge funds and large institutions have $1.55B invested in TG Therapeutics in 2023 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 77 increasing their positions, 71 reducing their positions, and 39 closing their positions.
103% more capital invested
Capital invested by funds: $763M → $1.55B (+$787M)
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
34% more call options, than puts
Call options by funds: $85.5M | Put options by funds: $63.8M
8% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 71
5% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 39
0% more funds holding
Funds holding: 235 → 235 (0)
0.17% less ownership
Funds ownership: 60.06% → 59.89% (-0.17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$47M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
+$29.8M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$18.8M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$11.9M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$26M |
| 2 |
Two Sigma Investments
New York
|
-$25.4M |
| 3 |
State Street
Boston,
Massachusetts
|
-$18.2M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$16.8M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$13.5M |
TGTX Hedge Fund Activity: Q4 2023 in Review
235 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q4 2023, worth a combined $1.55B — up 103% from $763M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new TGTX positions and 39 closed out — a net gain of 2 holders — while 77 added to existing stakes and 71 trimmed.
The largest buyer was Darwin Global Management, opening a new position worth an estimated $47M. The largest seller was Soleus Capital Management, cutting an estimated $26M.
- 235 institutional investors held TG Therapeutics (TGTX) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $1.55B of TG Therapeutics stock for Q4 2023, up 103% quarter-over-quarter.
- 41 funds opened new TG Therapeutics positions in Q4 2023 and 39 closed out, a net change of +2 holders.
- The largest TG Therapeutics buyer in Q4 2023 was Darwin Global Management, an estimated $47M added.
- The largest TG Therapeutics seller in Q4 2023 was Soleus Capital Management, an estimated $26M sold.
Based on aggregated 13F filings for Q4 2023.